Telix Pharmaceuticals announced that it agreed to acquire radioisotope production technology firm ARTMS Inc. ARTMS also brings with it an advanced cyclotron-based isotope production platform and manufacturing plant. It has a stockpile of ultra-pure rare metals required for consumable target production, too, according to a news release. The company specializes in the physics, chemistry and…
BD lays off 100 at biotech reagent plant in California
BD recently informed California’s Employment Development Department that it will relocate its Biosciences division’s reagent manufacturing and R&D operations in San Jose. The Life Sciences tech giant is laying off roughly 100 workers due to the relocation to other BD sites, according to its WARN letter dated Dec. 12, 2023. The layoffs have been taking…
Bora Pharmaceuticals is buying generics maker Upsher-Smith
Bora Pharmaceuticals announced that its board approved the acquisition of Upsher-Smith Laboratories for up to $210 million. Minnesota-based Upsher-Smith features a diversified portfolio of 48 generic products. It has manufacturing facilities in Plymouth and Maple Grove, Minnesota. Taipei, Taiwan-based Bora called the company a reliable partner with solid manufacturing capabilities, a robust distribution network and…
Novartis opens new radioligand therapy manufacturing facility in Indianapolis
Novartis today announced the expansion of its radioligand therapy (RLT) manufacturing capabilities with a new facility in Indianapolis. The Basil, Switzerland–based pharma giant said it has received FDA approval for commercial manufacturing in Indianapolis of its RLT therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat advanced metastatic prostate cancer. The new 70,000-square foot facility…
Biden’s supply chain plans include made-in-America medicines
The Biden administration recently announced efforts to strengthen the pharmaceutical supply chain, mitigate shortages of essential medicines, and expand domestic manufacturing. The new efforts are part of an overall package of initiatives to boost U.S. supply chains that the White Houe announced on Nov. 27. Securing the country’s supply of medicines and lowering prices have…
Navigating the new regulatory terrain pharma companies face with IRA and 340B
The ever-evolving landscape of pharmaceutical regulations has long been challenging to navigate, but now pharma companies face additional complexities with the introduction of the Inflation Reduction Act (IRA) and the ongoing implementation of the 340B drug pricing program. In recent years, the IRA has made waves for its impact on the pharmaceutical industry, including proposals…
Decade-plus review of drug recall trends from 2011 to 2023
Earlier this year, we took a look at the most common causes of drug-related recalls in 2022 and the first quarter of 2023. Now, we are expanding our lens to examine drug-related FDA recalls from 2011 to 2023. Understanding the recall landscape In recent decades, prominent incidents like the Tylenol poisonings in 1982 have underscored…
Gilead wins ruling in battle against alleged counterfeiters in HIV drug case
A federal judge ruled against two defendants accused of selling counterfeit HIV medications, denying their motions to lift existing asset freezes obtained by pharmaceutical company Gilead Sciences in the ongoing lawsuit. Judge Ann M. Donnelly of the United States District Court for the Eastern District of New York converted the temporary asset freezes into preliminary…
The need for a data-driven culture in life sciences: What you don’t know can hurt you
Preventing sudden failures and unexpected downtime in life sciences organizations starts with promoting a data-driven culture across the enterprise. Promoting a data-driven culture across the enterprise is what makes today’s most successful life sciences organizations stand out. Efficient operations are only possible when the processes underlying those activities are functional, and this type of reliable…
The economics behind the Adderall shortage: Why low prices lead to scarcity
On October 12, 2022, the FDA confirmed what many patients with attention-deficit / hyperactivity disorder (ADHD) already knew: There was a shortage of the immediate-release formulation of amphetamine mixed salts commonly known by the brand name Adderall. The implications of this announcement have rippled across the United States, affecting scores of patients reliant on the…